[Second-line chemotherapy for colorectal cancer].
For the current metastatic colorectal cancer, FOLFIRI or FOLFOX is chosen as first-line chemotherapy. Second-line irinotecan-based chemotherapy is commonly used after first-line oxaliplatin-based chemotherapy. Of course, FOLFOX becomes the second-line if FOLFIRI becomes primary therapy. It is important that these regimens combine molecular targetting agents such as Bevacizumab or Cetuximab. The addition of these new agents offers a chance to further enhance the activity of conventional chemotherapy.
Komatsu
Yoshito
Y
Hokkaido University Hospital Cancer Center, Sapporo, Japan.
Sogabe
Susumu
S
Kawamoto
Yasuyuki
Y
Iwanaga
Ichiro
I
Uehata
Yasuko
Y
Yuki
Satoshi
S
Asaka
Masahiro
M
D000970:Antineoplastic Agents / Q000276:immunology / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy; D012008:Recurrence; D015996:Survival Rate
D000970:Antineoplastic Agents